高级检索
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 诊疗方案 •
ENGLISH ABSTRACT
奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见
中华医学会呼吸病学分会
中国医师协会呼吸医师分会危重症医学专家组
作者及单位信息
·
DOI： 10.3760/cma.j.cn112147-20221230-00994
Expert consensus on treatment of severe COVID-19 caused by Omicron variants
Chinese Thoracic Society
Chinese Association of Chest Physicians Critical Care Group
Zhan Qingyuan
Xie Lixin
Liang Zong′an
Authors Info & Affiliations
Chinese Thoracic Society
Chinese Association of Chest Physicians Critical Care Group
Zhan Qingyuan
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital,National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Diseases,Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
Xie Lixin
College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing 100091, China
Liang Zong′an
Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu 610041, China
·
DOI： 10.3760/cma.j.cn112147-20221230-00994
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

近期全国多地出现奥密克戎（Omicron）变异株所致的重症新型冠状病毒感染（COVID-19）。重症救治是目前我国医疗机构面临的最大挑战，如何程序化、规范化地管理这些患者，最大限度地降低病死率，是每位不同专业背景的一线医务人员都要面临的问题。因此，中华医学会呼吸病学分会危重症学组与中国医师协会呼吸病学分会危重症医学专家组共同发起并组织呼吸与危重症专家，基于目前的循证医学证据及临床实践，撰写本推荐意见，以期规范重症患者的临床救治。

ABSTRACT

Severe novel coronavirus infection (COVID-19) caused by Omicron variants has arisen in many places of China recently, and critical care is currently the biggest challenge for medical institutions in China. How to manage these patients in a procedural and standardized way to minimize the mortality is a problem that the medical staff with different professional backgrounds has to face. Therefore, the Chinese Thoracic Society and Chinese Association of Chest Physicians Critical Care Group jointly initiated and organized pulmonary and critical care experts to write this recommendation based on the current medical evidence and clinical practice, in order to standardize the clinical treatment of critically ill patients.

Zhan Qingyuan, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital,National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Diseases,Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China, Email: mocdef.3ab61yqnahzrd
Xie Lixin, College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing 100091, China, Email: mocdef.6ab21103xleix
Liang Zong′an, Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital, Sichuan University, Chengdu 610041, China, Email: nc.defudabe.ucsazgnail
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

中华医学会呼吸病学分会,中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见[J]. 中华结核和呼吸杂志,2023,46(02)：101-110.

DOI:10.3760/cma.j.cn112147-20221230-00994

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

近期全国多地出现奥密克戎（Omicron）变异株所致的新型冠状病毒感染（COVID-19）。如何规范不同专业背景的一线医务人员管理这类患者，最大限度地降低病死率，是重症救治面临的最大挑战。为此，中华医学会呼吸病学分会危重症学组与中国医师协会呼吸医师分会危重症医学专家组共同发起并组织呼吸与危重症专家，基于目前的循证医学证据及临床实践，制定了本推荐意见。推荐意见适用于重型及危重型患者。考虑到药物的可及性，关于抗病毒及抗炎药物的推荐仅覆盖中国大陆地区目前能获取的药物。本推荐意见将动态更新。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Wolter N , Jassat W , Walaza S , et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399(10323):437-446. DOI: 10.1016/S0140-6736(22)00017-4 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
de Prost N , Audureau E , Heming N , et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19[J]. Nat Commun, 2022, 13(1):6025. DOI: 10.1038/s41467-022-33801-z .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Zheng H , Cao Y , Chen X , et al. Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study[J]. Cell Res, 2022, 32(8):781-784. DOI: 10.1038/s41422-022-00674-2 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Chen X , Yan X , Sun K , et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022[J]. Emerg Microbes Infect, 2022, 11(1):2800-2807. DOI: 10.1080/22221751.2022.2128435 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Agarwal A , Rochwerg B , Lamontagne F , et al. A living WHO guideline on drugs for covid-19[J]. BMJ, 2020, 370:m3379. DOI: 10.1136/bmj.m3379 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
国务院应对新型冠状病毒肺炎疫情联防联控机制综合组. 新型冠状病毒肺炎防控方案(第九版)[EB/OL]. [ 2022-06-27]. http://www.gov.cn/xinwen/2022-06/28/content_5698168.htm.
返回引文位置Google Scholar
百度学术
万方数据
[7]
Hyams C , Challen R , Marlow R , et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom[J]. Lancet Reg Health Eur, 2023, 25:100556. DOI: 10.1016/j.lanepe.2022.100556 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Esper FP , Adhikari TM , Tu ZJ , et al. Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants[J]. J Infect Dis, 2022. DOI: 10.1093/infdis/jiac411 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Kunutsor SK , Laukkanen JA . Cardiovascular complications in COVID-19: A systematic review and meta-analysis[J]. J Infect, 2020, 81(2):e139-e141. DOI: 10.1016/j.jinf.2020.05.068 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Nchioua R , Diofano F , Noettger S , et al. Strong attenuation of SARS-CoV-2 Omicron BA.1 and increased replication of the BA.5 subvariant in human cardiomyocytes[J]. Signal Transduct Target Ther, 2022, 7(1):395. DOI: 10.1038/s41392-022-01256-9 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Teng L , Sun N , Chang W . Analysis of age-based stratified renal involvement in Tianjin first batch of 430 patients with Omicron variant of novel coronavirus infection[J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2022, 34(5):465-470. DOI: 10.3760/cma.j.cn121430-20220328-00303 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Law N , Chan J , Kelly C , et al. Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta, Omicron variants and vaccines[J]. Emerg Radiol, 2022, 29(4):625-629. DOI: 10.1007/s10140-022-02039-z .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Henry BM , de Oliveira M , Benoit S , et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis[J]. Clin Chem Lab Med, 2020, 58(7):1021-1028. DOI: 10.1515/cclm-2020-0369 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Liu F , Li L , Xu M , et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19[J]. J Clin Virol, 2020, 127:104370. DOI: 10.1016/j.jcv.2020.104370 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Escadafal C , Incardona S , Fernandez-Carballo BL , et al. The good and the bad: using C reactive protein to distinguish bacterial from non-bacterial infection among febrile patients in low-resource settings[J]. BMJ Glob Health, 2020, 5(5). DOI: 10.1136/bmjgh-2020-002396 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Ruan Q , Yang K , Wang W , et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China[J]. Intensive Care Med, 2020, 46(5):846-848. DOI: 10.1007/s00134-020-05991-x .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Wang L , He W , Yu X , et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up[J]. J Infect, 2020, 80(6):639-645. DOI: 10.1016/j.jinf.2020.03.019 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Qeadan F , Tingey B , Gu LY , et al. Prognostic values of serum ferritin and D-dimer trajectory in patients with COVID-19[J]. Viruses, 2021, 13(3). DOI: 10.3390/v13030419 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Yang X , Yu Y , Xu J , et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5):475-481. DOI: 10.1016/S2213-2600(20)30079-5 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Xu B , Fan CY , Wang AL , et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China[J]. J Infect, 2020, 81(1):e51-e60. DOI: 10.1016/j.jinf.2020.04.012 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Xia XY , Wu J , Liu HL , et al. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19[J]. J Clin Virol, 2020, 127:104360. DOI: 10.1016/j.jcv.2020.104360 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Long L , Zeng X , Zhang X , et al. Short-term outcomes of COVID-19 and risk factors for progression[J]. Eur Respir J, 2020, 55(5). DOI: 10.1183/13993003.00990-2020 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Butler CC , Hobbs F , Gbinigie OA , et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial[J]. Lancet, 2022. DOI: 10.1016/S0140-6736(22)02597-1 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Imai M , Ito M , Kiso M , et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB[J]. N Engl J Med, 2022. DOI: 10.1056/NEJMc2214302 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Horby P , Lim WS , Emberson JR , et al. Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8):693-704. DOI: 10.1056/NEJMoa2021436 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Tomazini BM , Maia IS , Cavalcanti AB , et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the coDEX randomized clinical trial[J]. JAMA, 2020, 324(13):1307-1316. DOI: 10.1001/jama.2020.17021 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Wu C , Chen X , Cai Y , et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med, 2020, 180(7):934-943. DOI: 10.1001/jamainternmed.2020.0994 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Angus DC , Derde L , Al-Beidh F , et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial[J]. JAMA, 2020, 324(13):1317-1329. DOI: 10.1001/jama.2020.17022 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Kalil AC , Patterson TF , Mehta AK , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19[J]. N Engl J Med, 2021, 384(9):795-807. DOI: 10.1056/NEJMoa2031994 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Marconi VC , Ramanan AV , de Bono S , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial[J]. Lancet Respir Med, 2021, 9(12):1407-1418. DOI: 10.1016/S2213-2600(21)00331-3 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Guimarães PO , Quirk D , Furtado RH , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia[J]. N Engl J Med, 2021, 385(5):406-415. DOI: 10.1056/NEJMoa2101643 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial[J]. Lancet, 2021, 397(10285): 1637-1645. DOI: 10.1016/s0140-6736(21)00676-0 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Gordon AC , Mouncey PR , Al-Beidh F , et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19[J]. N Engl J Med, 2021, 384(16):1491-1502. DOI: 10.1056/NEJMoa2100433 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Poor HD . Pulmonary Thrombosis and thromboembolism in COVID-19[J]. Chest, 2021, 160(4):1471-1480. DOI: 10.1016/j.chest.2021.06.016 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Wichmann D , Sperhake JP , Lütgehetmann M , et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study[J]. Ann Intern Med, 2020, 173(4):268-277. DOI: 10.7326/M20-2003 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Zhai Z , Li C , Chen Y , et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 Infection: a consensus statement before guidelines[J]. Thromb Haemost, 2020, 120(6):937-948. DOI: 10.1055/s-0040-1710019 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
National Institutes of Health. NIH COVID-19 treatment guidelines[EB/OL]. [ 2022-04-22]. https://www.covid19treatmentguidelines.nih.gov/.
返回引文位置Google Scholar
百度学术
万方数据
[38]
Cuker A , Tseng EK , Nieuwlaat R , et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients[J]. Blood Adv, 2022, 6(17):4915-4923. DOI: 10.1182/bloodadvances.2022007561 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Schulman S , Sholzberg M , Spyropoulos AC , et al. ISTH guidelines for antithrombotic treatment in COVID-19[J]. J Thromb Haemost, 2022, 20(10):2214-2225. DOI: 10.1111/jth.15808 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Lawler PR , Goligher EC , Berger JS , et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19[J]. N Engl J Med, 2021, 385(9):790-802. DOI: 10.1056/NEJMoa2105911 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Sholzberg M , Tang GH , Rahhal H , et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial[J]. BMJ, 2021, 375:n2400. DOI: 10.1136/bmj.n2400 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Spyropoulos AC , Goldin M , Giannis D , et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial[J]. JAMA Intern Med, 2021, 181(12):1612-1620. DOI: 10.1001/jamainternmed.2021.6203 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Cuker A , Tseng EK , Schünemann HJ , et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients[J]. Blood Adv, 2022, 6(17):4975-4982. DOI: 10.1182/bloodadvances.2022007940 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Goligher EC , Bradbury CA , McVerry BJ , et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19[J]. N Engl J Med, 2021, 385(9):777-789. DOI: 10.1056/NEJMoa2103417 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Sadeghipour P , Talasaz AH , Rashidi F , et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial[J]. JAMA, 2021, 325(16):1620-1630. DOI: 10.1001/jama.2021.4152 .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Siemieniuk R , Chu DK , Kim LH , et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline[J]. BMJ, 2018, 363:k4169. DOI: 10.1136/bmj.k4169 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
Alhazzani W , Møller MH , Arabi YM , et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)[J]. Intensive Care Med, 2020, 46(5):854-887. DOI: 10.1007/s00134-020-06022-5 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Disease Coronavirus 2019 (COVID-19) treatment guidelines[M]. Bethesda (MD), 2021.
返回引文位置
[49]
Evans L , Rhodes A , Alhazzani W , et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Crit Care Med, 2021, 49(11):e1063-e1143. DOI: 10.1097/CCM.0000000000005337 .
返回引文位置Google Scholar
百度学术
万方数据
[50]
Ospina-Tascón GA , Calderón-Tapia LE , García AF , et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial[J]. JAMA, 2021, 326(21):2161-2171. DOI: 10.1001/jama.2021.20714 .
返回引文位置Google Scholar
百度学术
万方数据
[51]
Raoof S , Nava S , Carpati C , et al. High-flow, noninvasive ventilation and awake (nonintubation) proning in patients with coronavirus disease 2019 with respiratory failure[J]. Chest, 2020, 158(5):1992-2002. DOI: 10.1016/j.chest.2020.07.013 .
返回引文位置Google Scholar
百度学术
万方数据
[52]
Attaway AH , Scheraga RG , Bhimraj A , et al. Severe covid-19 pneumonia: pathogenesis and clinical management[J]. BMJ, 2021, 372:n436. DOI: 10.1136/bmj.n436 .
返回引文位置Google Scholar
百度学术
万方数据
[53]
Kangelaris KN , Ware LB , Wang CY , et al. Timing of intubation and clinical outcomes in adults with acute respiratory distress syndrome[J]. Crit Care Med, 2016, 44(1):120-129. DOI: 10.1097/CCM.0000000000001359 .
返回引文位置Google Scholar
百度学术
万方数据
[54]
Ehrmann S , Li J , Ibarra-Estrada M , et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial[J]. Lancet Respir Med, 2021, 9(12):1387-1395. DOI: 10.1016/S2213-2600(21)00356-8 .
返回引文位置Google Scholar
百度学术
万方数据
[55]
Fan E , Del Sorbo L , Goligher EC , et al. An official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2017, 195(9):1253-1263. DOI: 10.1164/rccm.201703-0548ST .
返回引文位置Google Scholar
百度学术
万方数据
[56]
中华医学会呼吸病学分会呼吸危重症医学学组. 急性呼吸窘迫综合征患者机械通气指南(试行)[J]. 中华医学杂志, 2016, 96(6):404-424. DOI: 10.3760/cma.j.issn.0376-2491.2016.06.002 .
返回引文位置Google Scholar
百度学术
万方数据
[57]
中国医师协会呼吸医师分会危重症医学专业委员会, 中华医学会呼吸病学分会危重症医学学组. 体外膜式氧合治疗成人重症呼吸衰竭推荐意见[J]. 中华结核和呼吸杂志, 2019, 42(9):660-684. DOI: 10.3760/cma.j.issn.1001-0939.2019.09.006 .
返回引文位置Google Scholar
百度学术
万方数据
[58]
Combes A , Hajage D , Capellier G , et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome[J]. N Engl J Med, 2018, 378(21):1965-1975. DOI: 10.1056/NEJMoa1800385 .
返回引文位置Google Scholar
百度学术
万方数据
[59]
中国医师协会体外生命支持专业委员会. 成人体外膜氧合循环辅助专家共识[J]. 中华医学杂志, 2018, 98(12):886-894. DOI: 10.3760/cma.j.issn.0376-2491.2018.12.003 .
返回引文位置Google Scholar
百度学术
万方数据
[60]
Rawson TM , Moore L , Zhu N , et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing[J]. Clin Infect Dis, 2020, 71(9):2459-2468. DOI: 10.1093/cid/ciaa530 .
返回引文位置Google Scholar
百度学术
万方数据
[61]
Baskaran V , Lawrence H , Lansbury LE , et al. Co-infection in critically ill patients with COVID-19: an observational cohort study from England[J]. J Med Microbiol, 2021, 70(4). DOI: 10.1099/jmm.0.001350 .
返回引文位置Google Scholar
百度学术
万方数据
[62]
Elabbadi A , Turpin M , Gerotziafas GT , et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia[J]. Infection, 2021, 49(3):559-562. DOI: 10.1007/s15010-020-01553-x .
返回引文位置Google Scholar
百度学术
万方数据
[63]
Zhu X , Ge Y , Wu T , et al. Co-infection with respiratory pathogens among COVID-2019 cases[J]. Virus Res, 2020, 285:198005. DOI: 10.1016/j.virusres.2020.198005 .
返回引文位置Google Scholar
百度学术
万方数据
[64]
Lai CC , Yu WL . COVID-19 associated with pulmonary aspergillosis: a literature review[J]. J Microbiol Immunol Infect, 2021, 54(1):46-53. DOI: 10.1016/j.jmii.2020.09.004 .
返回引文位置Google Scholar
百度学术
万方数据
[65]
Pan L , Mu M , Yang P , et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study[J]. Am J Gastroenterol, 2020, 115(5):766-773. DOI: 10.14309/ajg.0000000000000620 .
返回引文位置Google Scholar
百度学术
万方数据
[66]
Villapol S . Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome[J]. Transl Res, 2020, 226:57-69. DOI: 10.1016/j.trsl.2020.08.004 .
返回引文位置Google Scholar
百度学术
万方数据
[67]
Yeoh YK , Zuo T , Lui GC , et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19[J]. Gut, 2021, 70(4):698-706. DOI: 10.1136/gutjnl-2020-323020 .
返回引文位置Google Scholar
百度学术
万方数据
[68]
詹庆元, 解立新. 中国呼吸危重症患者营养支持治疗专家共识[J]. 中华医学杂志, 2020, 100(8): 573-585. DOI: 10.3760/cma.j.issn.0376‐2491.2020.08.004 .
返回引文位置Google Scholar
百度学术
万方数据
[69]
Yonekawa A , Shimono N . Clinical significance of COVID-19 and diabetes: in the pandemic situation of SARS-CoV-2 variants including Omicron (B.1.1.529)[J]. Biology (Basel), 2022, 11(3). DOI: 10.3390/biology11030400 .
返回引文位置Google Scholar
百度学术
万方数据
[70]
Rhodes A , Evans LE , Alhazzani W , et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43(3):304-377. DOI: 10.1007/s00134-017-4683-6 .
返回引文位置Google Scholar
百度学术
万方数据
[71]
Wargny M , Potier L , Gourdy P , et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study[J]. Diabetologia, 2021, 64(4):778-794. DOI: 10.1007/s00125-020-05351-w .
返回引文位置Google Scholar
百度学术
万方数据
[72]
Crouse AB , Grimes T , Li P , et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes[J]. Front Endocrinol (Lausanne), 2020, 11:600439. DOI: 10.3389/fendo.2020.600439 .
返回引文位置Google Scholar
百度学术
万方数据
[73]
中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志, 2016, 39(4):253-279. DOI: 10.3760/cma.j.issn.1001-0939.2016.04.005 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
詹庆元，中日友好医院呼吸中心呼吸与危重症医学科 国家呼吸医学中心 国家呼吸疾病临床研究中心 中国医学科学院呼吸病学研究院，北京100029，Email：mocdef.3ab61yqnahzrd
B
解立新，解放军总医院呼吸与危重症医学部，北京100091，Email：mocdef.6ab21103xleix
C
梁宗安，四川大学华西医院呼吸与危重症医学科，成都610041，Email：nc.defudabe.ucsazgnail
D
中华医学会呼吸病学分会, 中国医师协会呼吸医师分会危重症医学专家组. 奥密克戎变异株所致重症新型冠状病毒感染临床救治专家推荐意见[J]. 中华结核和呼吸杂志, 2023, 46(2): 101-110. DOI: 10.3760/cma.j.cn112147-20221230-00994.
E
所有作者声明无利益冲突
F
中央高水平医院临床科研业务费 (2022-NHLHCRF-LX-01-01)
中国医学科学院医学与健康科技创新工程项目 (2022-I2M-JB-016)
“十四五”国家重点研发计划项目 (2022YFC2504401)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
花粉-食物过敏综合征研究进展
刘爽 等
中华预防医学杂志 2023,57(09)
蓝光对豚鼠离焦性近视进展的抑制作用及其视锥细胞密度变化机制
邹蕾蕾 等
中华实验眼科杂志 2023,41(08)
瘢痕疙瘩发病机制研究进展
苏治国 等
中华整形外科杂志 2022,38(02)
急性胰腺炎发病机制的研究进展
郑智 等
中华肝胆外科杂志 2021,27(02)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大